-transparent.png){kind=logo}
Characterization of bombesin binding sites in healthy human lung was performed through direct binding techniques. There was limited binding in the absence of trypsin and chymotrypsin inhibitors, suggesting important activities of both enzymes in human lung and/or increased sensitivity of the bombesin sites toward them. In human lung membranes, bombesin, gastrin releasing peptide (GRP) and GRP-preferring bombesin receptor antagonists displaced [125I-Tyr4]bombesin binding with high affinities (36-177 nM), whereas neuromedin B possessed a lower affinity of 2878 nM. [D-F5Phe6,D-Ala11]bombesin-(6-13)-methyl ester, the most active GRP-preferring bombesin antagonist as yet reported, had the highest affinity among all antagonists tested whereas neuromedin B had the lowest affinity. These data demonstrate that the bombesin binding sites in the human lung are of the GRP-preferring type.
E Lach, and
D H Coy, and
P Dumont, and
Y Landry, and
J P Gies
April 1992,
Molecular and cellular neurosciences,
E Lach, and
D H Coy, and
P Dumont, and
Y Landry, and
J P Gies
August 2000,
Journal of the American Society of Nephrology : JASN,
E Lach, and
D H Coy, and
P Dumont, and
Y Landry, and
J P Gies
February 1992,
Neuropeptides,
E Lach, and
D H Coy, and
P Dumont, and
Y Landry, and
J P Gies
January 1993,
The American journal of physiology,
E Lach, and
D H Coy, and
P Dumont, and
Y Landry, and
J P Gies
January 1982,
Nihon rinsho. Japanese journal of clinical medicine,
E Lach, and
D H Coy, and
P Dumont, and
Y Landry, and
J P Gies
August 1997,
Biochemical Society transactions,
E Lach, and
D H Coy, and
P Dumont, and
Y Landry, and
J P Gies
August 1993,
European journal of pharmacology,
E Lach, and
D H Coy, and
P Dumont, and
Y Landry, and
J P Gies
July 1980,
Life sciences,
E Lach, and
D H Coy, and
P Dumont, and
Y Landry, and
J P Gies
January 1989,
Progress in growth factor research,
E Lach, and
D H Coy, and
P Dumont, and
Y Landry, and
J P Gies
November 1984,
The American journal of pathology,
